Carcinoid Heart Disease: How to Diagnose and Treat in 2020?
Neuroendocrine tumors (NETs, originally termed "carcinoids") create a relatively rare group of neoplasms with an approximate incidence rate of 2.5 to 5 cases per 100 000 persons. Roughly 30% to 40% of subjects with NETs develop carcinoid syndrome (CS), and 20% to 50% of subjects with CS are diagnose...
| Published in: | Clinical Medicine Insights: Cardiology Vol. 14; pp. 1 - 9 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | review tables/charts Journal Article |
| Published: |
Sage Publications Inc.
10/27/2020
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=146703615&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 146703615 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11795468 B3KL jtl: Clinical Medicine Insights: Cardiology issn: 11795468 maglogo: Y pubinfo: dt: 10/27/2020 vid: 14 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 146703615 146703615 146703615 10.1177/1179546820968101 146703615 ppf: 1 ppct: 8 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Carcinoid Heart Disease: How to Diagnose and Treat in 2020? aug: au: Bober, Barbara Saracyn, Marek Kołodziej, Maciej Kowalski, Łukasz Deptuła-Krawczyk, Elżbieta Kapusta, Waldemar Kamiński, Grzegorz Mozenska, Olga Bil, Jacek affil: Department of Endocrinology and Isotope Therapy, Military Institute of Medicine, Warsaw, Mazowieckie, Poland sug: subj: Heart Diseases Diagnosis Carcinoid Tumor Diagnosis Heart Diseases Therapy Carcinoid Tumor Therapy Serotonin Blood Somatostatin Therapeutic Use Cardiac Surgery Natriuretic Peptide, Brain Blood Indoles Blood Biological Markers Radioisotopes Diagnostic Use ab: Neuroendocrine tumors (NETs, originally termed "carcinoids") create a relatively rare group of neoplasms with an approximate incidence rate of 2.5 to 5 cases per 100 000 persons. Roughly 30% to 40% of subjects with NETs develop carcinoid syndrome (CS), and 20% to 50% of subjects with CS are diagnosed with carcinoid heart disease (CaHD). The long-standing exposure to high serum serotonin concentration is one of the crucial factors in CaHD development. White plaque-like deposits on the endocardial surface of heart structures with valve leaflets and subvalvular apparatus thickening (fused and shortened chordae; thickened papillary muscles) are characteristic for CaHD. NT pro-BNP and 5-hydroxyindoleacetic acid are the 2 most useful screening markers. Long-acting somatostatin analogs are the standard of care in symptoms control. They are also the first-line treatment for tumor control in subjects with a metastatic somatostatin receptor avid disease. In cases refractory to somatostatin analogs, several options are available. We can increase a somatostatin analog to off-label doses, add telotristat ethyl or administer peptide receptor radionuclide therapy. Cardiac surgery, which mainly involves valve replacement, is presently the most efficient strategy in subjects with advanced CaHD and can relieve unmanageable symptoms or be partly responsible for better prognosis. pubtype: Academic Journal doctype: review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|